Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

P3643

Supelco

Phenobarbital solution

1.0 mg/mL in methanol

Synonym(s):

5-Ethyl-5-phenylbarbituric acid solution

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C12H12N2O3
CAS Number:
50-06-6
Molecular Weight:
232.24
MDL number:
MFCD00066494
UNSPSC Code:
41116107
PubChem Substance ID:
329820184

grade

drug standard

drug control

Home Office Schedule 3; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada

concentration

1.0 mg/mL in methanol

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

2-8°C

SMILES string

CCC1(C(=O)NC(=O)NC1=O)c2ccccc2

InChI

1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)

InChI key

DDBREPKUVSBGFI-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Storage Class

3 - Flammable liquids

wgk_germany

WGK 1

flash_point_f

51.8 °F - closed cup

flash_point_c

11 °C - closed cup

ppe

Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
062K8804

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Lundqvist et al.
Acta paediatrica (Oslo, Norway : 1992), 102(9), 863-867 (2013-06-07)
Treatment of neonatal seizures still relies primarily on phenobarbital, despite an estimated efficacy of less than 50% and concern over neurodegenerative side effects. The objective of this study was to evaluate the efficacy and safety of lidocaine as second-line treatment
Martin J Brodie et al.
Epilepsia, 53 Suppl 8, 40-46 (2012-12-12)
This article reviews the current position of phenobarbital using articles published since 2000 and speculates on its likely future contribution to epilepsy care. Over the last decade there have been no major double-blind randomized placebo-controlled or comparative trials with phenobarbital.
Caroline A Crowther et al.
The Cochrane database of systematic reviews, (1)(1), CD000164-CD000164 (2010-01-22)
Preterm infants are at risk of periventricular haemorrhage. Phenobarbital might prevent ischaemic injury or reduce fluctuations in blood pressure and blood flow in the brain. To assess the benefits and harms of giving phenobarbital to women at risk of imminent
Kathrin Töllner et al.
Annals of neurology, 75(4), 550-562 (2014-03-13)
There is considerable interest in using bumetanide, a chloride importer Na-K-Cl cotransporter antagonist, for treatment of neurological diseases, such as epilepsy or ischemic and traumatic brain injury, that may involve deranged cellular chloride homeostasis. However, bumetanide is heavily bound to
Louis W C Chow et al.
Expert opinion on investigational drugs, 22(3), 299-307 (2013-02-12)
This prospective study aimed at investigating the efficacy and safety of the concurrent use of celecoxib (CXB) with 5-fluorouracil, epirubicin and cyclophosphamide (FEC), followed by docetaxel (T) in the neoadjuvant setting. A total of 64 invasive breast cancer patients were
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service